Literature DB >> 17097564

A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes.

Sreenath V Sharma1, Patrycja Gajowniczek, Inna P Way, Diana Y Lee, Jane Jiang, Yuki Yuza, Marie Classon, Daniel A Haber, Jeffrey Settleman.   

Abstract

"Oncogene addiction" describes an unexplained dependency of cancer cells on a particular cellular pathway for survival or proliferation. We report that differential attenuation rates of prosurvival and proapoptotic signals in oncogene-dependent cells contribute to cell death following oncogene inactivation. Src-, BCR-ABL-, and EGF receptor-dependent cells exhibit a similar profile of signal attenuation following oncogene inactivation characterized by rapid diminution of phospho-ERK, -Akt, and -STAT3/5, and a delayed accumulation of the proapoptotic effector phospho-p38 MAPK. These findings implicate a transient imbalance in survival and apoptotic oncogenic outputs in the apoptotic response to oncogene inactivation. Moreover, these observations implicate a common profile of signal attenuation for multiple oncogenes and suggest that "addiction" associated with apoptosis reflects an active rather than a passive process.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17097564      PMCID: PMC2673136          DOI: 10.1016/j.ccr.2006.09.014

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  37 in total

1.  Negative feedback regulation of ASK1 by protein phosphatase 5 (PP5) in response to oxidative stress.

Authors:  K Morita; M Saitoh; K Tobiume; H Matsuura; S Enomoto; H Nishitoh; H Ichijo
Journal:  EMBO J       Date:  2001-11-01       Impact factor: 11.598

2.  Essential role for oncogenic Ras in tumour maintenance.

Authors:  L Chin; A Tam; J Pomerantz; M Wong; J Holash; N Bardeesy; Q Shen; R O'Hagan; J Pantginis; H Zhou; J W Horner; C Cordon-Cardo; G D Yancopoulos; R A DePinho
Journal:  Nature       Date:  1999-07-29       Impact factor: 49.962

Review 3.  "Oncogenic shock": explaining oncogene addiction through differential signal attenuation.

Authors:  Sreenath V Sharma; Michael A Fischbach; Daniel A Haber; Jeffrey Settleman
Journal:  Clin Cancer Res       Date:  2006-07-15       Impact factor: 12.531

4.  Regulation of both apoptosis and cell survival by the v-Src oncoprotein.

Authors:  D Johnson; M Agochiya; K Samejima; W Earnshaw; M Frame; J Wyke
Journal:  Cell Death Differ       Date:  2000-08       Impact factor: 15.828

5.  SU6656, a selective src family kinase inhibitor, used to probe growth factor signaling.

Authors:  R A Blake; M A Broome; X Liu; J Wu; M Gishizky; L Sun; S A Courtneidge
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

6.  Reversible tumorigenesis by MYC in hematopoietic lineages.

Authors:  D W Felsher; J M Bishop
Journal:  Mol Cell       Date:  1999-08       Impact factor: 17.970

7.  Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation.

Authors:  Mayumi Ono; Akira Hirata; Takuro Kometani; Miho Miyagawa; Shu-ichi Ueda; Hisafumi Kinoshita; Teruhiko Fujii; Michihiko Kuwano
Journal:  Mol Cancer Ther       Date:  2004-04       Impact factor: 6.261

8.  Cloning and characterization of a thermolabile v-src gene for use in reversible transformation of mammalian cells.

Authors:  A C Maroney; S A Qureshi; D A Foster; J S Brugge
Journal:  Oncogene       Date:  1992-06       Impact factor: 9.867

Review 9.  STI571 as a targeted therapy for CML.

Authors:  Michael E O'Dwyer; Michael J Mauro; Brian J Druker
Journal:  Cancer Invest       Date:  2003-06       Impact factor: 2.176

10.  Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis.

Authors:  Z Xia; M Dickens; J Raingeaud; R J Davis; M E Greenberg
Journal:  Science       Date:  1995-11-24       Impact factor: 47.728

View more
  103 in total

1.  Dasatinib synergizes with both cytotoxic and signal transduction inhibitors in heterogeneous breast cancer cell lines--lessons for design of combination targeted therapy.

Authors:  Brian J Park; Zakary L Whichard; Seth J Corey
Journal:  Cancer Lett       Date:  2012-02-02       Impact factor: 8.679

2.  Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition.

Authors:  Mikhail A Nikiforov; Marybeth Riblett; Wen-Hua Tang; Vladimir Gratchouck; Dazhong Zhuang; Yolanda Fernandez; Monique Verhaegen; Sooryanarayana Varambally; Arul M Chinnaiyan; Andrzej J Jakubowiak; Maria S Soengas
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-27       Impact factor: 11.205

3.  The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP.

Authors:  Cai-Hong Yun; Kristen E Mengwasser; Angela V Toms; Michele S Woo; Heidi Greulich; Kwok-Kin Wong; Matthew Meyerson; Michael J Eck
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-28       Impact factor: 11.205

4.  Proteomic profiling identified multiple short-lived members of the central proteome as the direct targets of the addicted oncogenes in cancer cells.

Authors:  Tonggang Qi; Wei Zhang; Yun Luan; Feng Kong; Dawei Xu; Guanghui Cheng; Yunshan Wang
Journal:  Mol Cell Proteomics       Date:  2013-10-08       Impact factor: 5.911

Review 5.  Dormancy of metastatic melanoma.

Authors:  Liliana Ossowski; Julio A Aguirre-Ghiso
Journal:  Pigment Cell Melanoma Res       Date:  2009-10-19       Impact factor: 4.693

Review 6.  Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases.

Authors:  Andreas Strasser; Suzanne Cory; Jerry M Adams
Journal:  EMBO J       Date:  2011-08-23       Impact factor: 11.598

7.  Computational delineation of tyrosyl-substrate recognition and catalytic landscapes by the epidermal growth factor receptor tyrosine kinase domain.

Authors:  Yingting Liu; Ravi Radhakrishnan
Journal:  Mol Biosyst       Date:  2014-04-29

8.  Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F.

Authors:  Sigal Gery; Qi Cao; Saskia Gueller; Hongtao Xing; Ayalew Tefferi; H Phillip Koeffler
Journal:  J Leukoc Biol       Date:  2009-03-17       Impact factor: 4.962

9.  PME-1 protects extracellular signal-regulated kinase pathway activity from protein phosphatase 2A-mediated inactivation in human malignant glioma.

Authors:  Pietri Puustinen; Melissa R Junttila; Sari Vanhatupa; Anna A Sablina; Melissa E Hector; Kaisa Teittinen; Olayinka Raheem; Kirsi Ketola; Shujun Lin; Juergen Kast; Hannu Haapasalo; William C Hahn; Jukka Westermarck
Journal:  Cancer Res       Date:  2009-03-17       Impact factor: 12.701

10.  ERK2, but not ERK1, mediates acquired and "de novo" resistance to imatinib mesylate: implication for CML therapy.

Authors:  Clara I Aceves-Luquero; Anupriya Agarwal; Juan L Callejas-Valera; Laura Arias-González; Azucena Esparís-Ogando; Luis del Peso Ovalle; Itxaso Bellón-Echeverria; Miguel A de la Cruz-Morcillo; Eva M Galán Moya; Inmaculada Moreno Gimeno; Juan C Gómez; Michael W Deininger; Atanasio Pandiella; Ricardo Sánchez Prieto
Journal:  PLoS One       Date:  2009-07-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.